Form 6-K Cardiol Therapeutics For: Sep 23

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

 

 

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated September 23, 2026 - Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: September 23, 2026	By:	/s/ Christopher Waddick
		Christopher Waddick
	Title:	Chief Financial Officer

 

 

ATTACHMENTS / EXHIBITS

NEWS RELEASE DATED SEPTEMBER 23, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SAN SIMEON ESTATE OPENS MODERN WINE AND CULINARY DESTINATION IN PASO ROBLES' WILLOW CREEK DISTRICT
• New Anglia University Examines How International Clinical Networks Are Expanding Opportunities for British Medical Students
• West Red Lake Gold Reports Q3 2026 Production and Continued Operational Momentum at the Madsen Mine